Cost of Achieving Relevant Composite Endpoint of HbA1c<7%, No Hypoglycaemia and Weight Loss of ≥3% in a 52 Week Post-Hoc Analysis of Dapagliflozin Versus Glipizide
Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.666
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2013
Authors
Publisher
Elsevier BV